Once the molecular aberrations in a cancer are understood, drugs can be designed with a rational approach to treat the cancer. Which of the following is NOT true regarding such drugs?

A) The drug imatinib (Gleevec) can inhibit the chimeric tyrosine kinase Bcr-Abl in chronic myelogenous leukemia (CML).
B) Even if a protein is not the product of a cancer-critical gene, drugs that specifically block its activity can be effective in curing cancer.
C) Imatinib is most effective in treating chronic myelogenous leukemia (CML) in its acute blast-crisis phase.
D) Protein kinases have turned out to be relatively easy to inhibit with small molecules.
E) The success of imatinib relies on the phenomenon of oncogene dependence in cancer cells.